This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cytokinetics Scores Amgen Deal

Shares of Cytokinetics (CYTK - Get Report) soared after its partner Amgen (AMGN - Get Report) set plans to work on a new heart failure treatment.

Amgen will pay Cytokinetics an upfront payment of $42 million for licensing and access to its technology. It will purchase 3.5 million Cytokinetics shares at $9.47 a share.

Cytokinetics stock were gaining 14.2% to $8.54, while Amgen's shares rose 1.6% to $69.37.

The collaboration, which is worldwide outside of Japan, involves the discovery, development and marketing of a new treatment intended to activate heart muscle contractions. During the first two years of the plan, Cytokinetics will fund its own research. If the drug's development meets predefined criteria and certain other conditions are satisfied, Amgen will exercise an option to take over development and pay Cytokinetics a $50 million exercise fee.

Cytokinetics may also be eligible to receive payments of up to $600 million related to its lead drug, called CK-1827452, and other treatments developed as a result of the research. It may also receive royalties on sales of the drugs, and increase royalty gains if it helps fund late-stage human trials.

In that case, Cytokinetics could co-promote its drugs in North America at Amgen's expense. If Amgen chooses not to exercise its option, the collaboration agreement would end and Cytokinetics may choose to independently develop the drug.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $154.18 -1.39%
CYTK $8.16 -2.86%
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs